Abstrakt

Viruses cause many diseases in humans, from self-resolving diseases to acute fatal diseases. New antiviral drugs are registered and the efficacy and safety of other medicines are evaluated in clinical trials. Antiviral therapy significantly reduces the morbidity and mortality of patients, but may cause numerous adverse effects. The aim of this study is to discuss the mechanism, selected adverse effects of available antivirals and their safety during pregnancy and lactation. The authors refer to the classification of drugs used during pregnancy and recommendations for breastfeeding, which, for example, definitely prohibit the use of ribavirin. The authors also pay attention to the monitoring of selected diagnostic parameters to improve the treatment results. Clinicians should limit adverse effects through an individual, specific to the patient treatment regimen. Physicians should pay special attention to the use of antiviral drugs in pregnant and breast-feeding women. Clinical trials should be continued to increase knowledge about the adverse effects of antiviral medicines.

Przypisy

• 1. Adalsteinsson J.A., Pan M., Kaushik S., Ungar J.: Foscarnet-inducedgenital lesions: An overview with a case report. Dermatol.Reports, 2018; 10: 7749
  Google Scholar
• 2. Aldara – Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/aldara-epar-product-information_en.pdf (10.05.2019)
  Google Scholar
• 3. Alpivab – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/alpivab-epar-product–information_en.pdf (10.08.2018)
  Google Scholar
• 4. Alvarez-McLeod A., Havlik J., Drew K.E.: Foscarnet treatment of genitalinfection due to acyclovir-resistant herpes simplex virus type 2 in a pregnantpatient with AIDS: case report. Clin. Infect. Dis., 1999; 29: 937–938
  Google Scholar
• 5. Alves Galvão M.G., Rocha Crispino Santos M.A., Alves da CunhaA.J.: Amantadine and rimantadine for influenza A in children and theelderly. Cochrane Database Syst. Rev., 2014; 2014: CD002745
  Google Scholar
• 6. Asunaprevir – Summary of Product Characteristics. http://www.medicines.org.au/files/bqpsunve.pdf (10.08.2018)
  Google Scholar
• 7. Balsat M., Etienne M., Elhamri M., Hayette S., Salles G, Thomas X.:Successful pregnancies in patients with BCR-ABL-positive leukemiastreated with interferon-alpha therapy during the tyrosine kinaseinhibitors era. Eur. J. Haematol., 2018; 101: 774–780
  Google Scholar
• 8. Baraclude – Summary of Product Characteristics.https://ec.europa.eu/health/documents/community-register/2017/20170303137253/anx_137253_en.pdf (10.08.2018)
  Google Scholar
• 9. Berenguer M., Prieto M., Rayón M., Bustamante M., Carrasco D.,Moya A., Pastor M.A., Gobernado M., Mir J., Berenguer J.: Famciclovirtreatment in transplant recipients with HBV-related liver disease:disappointing results. Am. J. Gastroenterol., 2001; 96: 526–533
  Google Scholar
• 10. Bornhede R., Soeria-Atmadja S., Westling K., Pettersson K., NavérL.: Dolutegravir in pregnancy-effects on HIV-positive women andtheir infants. Eur. J. Clin. Microbiol. Infect. Dis., 2018; 37: 495–500
  Google Scholar
• 11. Bowman L.J., Melaragno J.I., Brennan D.C.: Letermovir for themanagement of cytomegalovirus infection. Expert Opin. Investig.Drugs, 2017; 26: 235–241
  Google Scholar
• 12. Briggs G.G., Freeman R.K.: Drug in Pregnancy and Lactacion: AReference Guide to Fetal and Neonatal Risk. Lippincott Williams andWilkins, Philadelphia 2014
  Google Scholar
• 13. Brik A., Wong C.H.: HIV-1 protease: mechanism and drug discovery.Org. Biomol. Chem., 2003; 1: 5–14
  Google Scholar
• 14. Brivudine – Information for the user. http://mri.cts-mrp.eu/download/DE_H_0343_001_FinalPI_2of3.pdf (10.08.2018)
  Google Scholar
• 15. Bukhari S.A., Ahmed M.M., Anjum F., Anwar H., Naqvi S.A., ZahraT., Batool U.: Post interferon therapy decreases male fertilitythrough gonadotoxic effect. Pak. J. Pharm. Sci., 2018; 31: 1565–1570
  Google Scholar
• 16. Carpenter C.C., Fischl M.A., Hammer S.M., Hirsch M.S., JacobsenD.M., Katzenstein D.A., Montaner J.S., Richman D.D., Sáag M.S., SchooleyR.T., Thompson M.A., Vella S., Yeni P.G., Volberding P.A.: Antiretroviraltherapy for HIV infection in 1996. Recommendations of an internationalpanel. International AIDS Society-USA. JAMA, 1996; 276: 146–154
  Google Scholar
• 17. Celsentri – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/celsentri-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 18. Chou S., Ercolani R.J., Derakhchan K.: Antiviral activity of maribavirin combination with other drugs active against human cytomegalovirus.Antiviral Res., 2018; 157: 128-133
  Google Scholar
• 19. Cottrell E.B., Chou R., Wasson N., Rahman B., Guise J.M.: Reducingrisk for mother-to-infant transmission of hepatitis C virus: asystematic review for the U.S. Preventive Services Task Force. Ann.Intern. Med., 2013; 158: 109–113
  Google Scholar
• 20. Crixivan – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/crixivan-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 21. Crumpacker C.S.: Mechanism of action of foscarnet against viralpolymerases. Am. J. Med., 1992; 92: 3S–7S
  Google Scholar
• 22. Cymevene – Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/referral/cymevene-article-30-referral-annex-iii_en.pdf (10.08.2018)
  Google Scholar
• 23. Dabis F., Msellati P., Meda N., Welffens-Ekra C., You B., ManigartO., Leroy V., Simonon A., Cartoux M., Combe P., Ouangré A., RamonR., Ky-Zerbo O., Montcho C., Salamon R., Rouzioux C., Van de Perre P.,Mandelbrot L.: 6-month efficacy, tolerance, and acceptability of a shortregimen of oral zidovudine to reduce vertical transmission of HIV inbreastfed children in Côte d’Ivoire and Burkina Faso: a double-blindplacebo-controlled multicentre trial. DITRAME Study Group. DIminutionde la Transmission Mère-Enfant. Lancet, 1999; 353: 786–792
  Google Scholar
• 24. Daklinza – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/daklinza-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 25. Das K., Aramini J.M., Ma L.C., Krug R.M., Arnold E.: Structuresof influenza A proteins and insights into antiviral drug targets. Nat.Struct. Mol. Biol., 2010; 17: 530-538
  Google Scholar
• 26. De Clercq E.: Selective anti-herpesvirus agents. Antivir. Chem.Chemother., 2013; 23: 93–101
  Google Scholar
• 27. De Clercq E.: The nucleoside reverse transcriptase inhibitors,nonnucleoside reverse transcriptase inhibitors, and protease inhibitorsin the treatment of HIV infections (AIDS). Adv. Pharmacol.,2013; 67: 317–358
  Google Scholar
• 28. De Clercq E., Li G.: Approved antiviral drugs over the past 50years. Clin. Microbiol. Rev., 2016; 29: 695–747
  Google Scholar
• 29. Donnelly R.P., Dickensheets H., O’Brien T.R.: Interferon-lambdaand therapy for chronic hepatitis C virus infection. Trends Immunol.,2011; 32: 443–450
  Google Scholar
• 30. Edurant – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/edurant-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 31. Emtriva – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/emtriva-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 32. Exviera – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/exviera-epar-product-information_en.pdf (10.08.2018)
  Google Scholar
• 33. Faith S.C., Durrani A.F., Jhanji V.: Cytomegalovirus keratitis. Curr.Opin. Ophthalmol., 2018; 29: 373–377
  Google Scholar
• 34. Famciclovir –Summary of Product Characteristics. http://chpl.com.pl/data_files/2011-07-14_004_FAM250_SPC_PL_final_clean.docx(10.08.2018)
  Google Scholar
• 35. Ferenci P., Bernstein D., Lalezari J., Cohen D., Luo Y., Cooper C.,Tam E., Marinho R.T., Tsai N., Nyberg A., Box T.D., Younes Z., EnayatiP., Green S., Baruch Y., et al.: ABT-450/r-ombitasvir and dasabuvir withor without ribavirin for HCV. N. Engl. J. Med., 2014; 370: 1983–1992
  Google Scholar
• 36. Fuzeon – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/fuzeon-epar-product-information_en.pdf (10.08.2018)
  Google Scholar
• 37. Genvoya – Summary of Product Characteristics.https://ec.europa.eu/health/documents/community-register/2017/20170324137350/anx_137350_en.pdf (10.08.2018)
  Google Scholar
• 38. Griffiths C., Drews S.J., Marchant D.J.: Respiratory syncytial virus:Infection, detection, and new options for prevention and treatment.Clin. Microbiol. Rev., 2017; 30: 277–319
  Google Scholar
• 39. Guclu E., Karabay O.: Choice of drugs in the treatment of chronichepatitis B in pregnancy. World J. Gastroenterol., 2013; 19: 1671–1672
  Google Scholar
• 40. Gupta A.K., Cherman A.M., Tyring S.K.: Viral and nonviral usesof imiquimod: a review. J. Cutan. Med. Surg., 2004; 8: 338–352
  Google Scholar
• 41. Harvoni – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/harvoni-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 42. Hazuda D.J.: HIV integrase as a target for antiretroviral therapy.Curr. Opin. HIV AIDS, 2012; 7: 383–389
  Google Scholar
• 43. Hepsera – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/hepsera-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 44. Hosseini I., Mac Gabhann F.: APOBEC3G-augmented stem celltherapy to modulate HIV replication: A computational study. PLoSOne, 2013; 8: e63984
  Google Scholar
• 45. Huang M., Jiang J.D., Peng Z.: Recent advances in the anti-HCVmechanisms of interferon. Acta Pharm. Sin. B., 2014; 4: 241–247
  Google Scholar
• 46. Hussar D.A., Tidwell W.P.: Elbasvir/grazoprevir, Velpatasvir/sofosbuvir,and Eteplirsen. J. Am. Pharm. Assoc., 2017; 57: 129–132
  Google Scholar
• 47. Hwang Y., Kim W., Kwon S.Y., Yu H.M., Kim J.H., Choe W.H.: Incidenceof and risk factors for thyroid dysfunction during peginterferonα and ribavirin treatment in patients with chronic hepatitisC. Korean J. Intern. Med., 2015; 30: 792–800
  Google Scholar
• 48. Intelence – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/intelence-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 49. Interferon Beta. https://www.ncbi.nlm.nih.gov/books/NBK501168/(10.05.2019)
  Google Scholar
• 50. Invirase – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/invirase-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 51. Isentress – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/isentress-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 52. Jeantils V., Alloui C., Rodrigues A., Bentata M., Peytavin G., CarbillonL.: Use of enfurvitide in pregnancy in HIV positive women inseven cases. Gynecol. Obstet. Fertil., 2009; 37: 396–400
  Google Scholar
• 53. Jefferson T., Jones M.A., Doshi P., Del Mar C.B., Hama R., ThompsonM.J., Spencer E.A., Onakpoya I., Mahtani K.R., Nunan D., Howick J., Heneghan C.J.: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane DatabaseSyst. Rev., 2014; 2014: CD008965
  Google Scholar
• 54. Jøraholmen M.W., Basnet P., Acharya G., Škalko-Basnet N.: PEGylatedliposomes for topical vaginal therapy improve delivery ofinterferon alpha. Eur. J. Pharm. Biopharm., 2017; 113: 132–139
  Google Scholar
• 55. Kanda T., Nakamoto S., Nakamura M., Jiang X., Miyamura T., WuS., Yokosuka O.: Direct-acting antiviral agents for the treatment ofchronic hepatitis C virus infection. J. Clin. Transl. Hepatol., 2014;2: 1–6
  Google Scholar
• 56. Kapić E., Becić F., Zvizdić S.: Enfuvirtide, mechanism of actionand pharmacological properties. Med. Arh., 2005; 59: 313–316
  Google Scholar
• 57. Keating G.M.: Ombitasvir/Paritaprevir/Ritonavir: A review inchronic HCV genotype 4 infection. Drugs, 2016; 76: 1203–1211
  Google Scholar
• 58. Khalil A., Jones C., Ville Y.: Congenital cytomegalovirus infection:management update. Curr. Opin. Infect. Dis., 2017; 30: 274–280
  Google Scholar
• 59. Laco G.S.: HIV-1 protease substrate-groove: Role in substraterecognition and inhibitor resistance. Biochimie, 2015; 118: 90–103
  Google Scholar
• 60. Lasfar A., Zloza A., Cohen-Solal K.A.: IFN-lambda therapy: currentstatus and future perspectives. Drug Discov. Today, 2016; 21:167–171
  Google Scholar
• 61. Lawitz E., Poordad F., Hyland R.H., Wang J., Liu L., Dvory-SobolH., Brainard D.M., McHutchison J.G., Gutierrez J.A.: Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCVinfection and cirrhosis: results from two Phase II studies. Antivir.Ther., 2016; 21: 679–687
  Google Scholar
• 62. Lee H.L., Phong T.V., Rohani A.: Effects of ribavirin and hydroxyureaon oral infection of Aedes aegypti (L.) with dengue virus.Southeast Asian J. Trop. Med. Public Health, 2012; 43: 1358–1364
  Google Scholar
• 63. Leung N., Peng C.Y., Hann H.W., Sollano J., Lao-Tan J., Hsu C.W.,Lesmana L., Yuen M.F., Jeffers L., Sherman M., Min A., MencariniK., Diva U., Cross A., Wilber R., Lopez-Talavera J.: Early hepatitis Bvirus DNA reduction in hepatitis B e antigen-positive patients withchronic hepatitis B: A randomized international study of entecavirversus adefovir. Hepatology, 2009; 49: 72–79
  Google Scholar
• 64. Lim S.G., Ng T.M., Kung N., Krastev Z., Volfova M., Husa P., LeeS.S., Chan S., Shiffman M.L., Washington M.K., Rigney A., AndersonJ., Mondou E., Snow A., Sorbel J., Guan R., Rousseau F.: A double-blindplacebo-controlled study of emtricitabine in chronic hepatitis B.Arch. Intern. Med., 2006; 166: 49–56
  Google Scholar
• 65. Lonsurf – Summary of Product Characteristics. https://ec.europa.eu/health/documents/community-register/2016/20160425134472/anx_134472_en.pdf (10.08.2018)
  Google Scholar
• 66. Masgala A., Nikolopoulos G., Tsiodras S., Bonovas S., SitarasN.M.: Antiviral drugs in the prophylaxis of HBV infection. Curr. Med.Chem., 2012; 19: 5940–5946
  Google Scholar
• 67. Matthews T., Boehme R.: Antiviral activity and mechanism ofaction of ganciclovir. Rev. Infect. Dis., 1988; 10: S490–S494
  Google Scholar
• 68. Maximova N., Antonio P., Marilena G., Rovere F., Tamaro P.:Complete remission of VZV reactivation treated with valganciclovirin a patient with total lymphocyte depletion and acute kidneyinjury after allogeneic bone marrow transplantation. APMIS, 2015;123: 77–80
  Google Scholar
• 69. McKimm-Breschkin J.L.: Influenza neuraminidase inhibitors:antiviral action and mechanisms of resistance. Influenza Other Respir.Viruses, 2013; 7: 25–36
  Google Scholar
• 70. Menéndez-Arias L., Álvarez M., Pacheco B.: Nucleoside/nucleotideanalog inhibitors of hepatitis B virus polymerase: mechanismof action and resistance. Curr. Opin. Virol., 2014; 8: 1–9
  Google Scholar
• 71. Minakami H., Kubo T., Nakai A., Saito S., Unno N.: Pregnancyoutcomes of women exposed to laninamivir during pregnancy. Pharmacoepidemiol.Drug Saf., 2014; 23: 1084–1087
  Google Scholar
• 72. Mofenson L.M., McIntyre J.A.: Advances and research directionsin the prevention of mother-to-child HIV-1 transmission. Lancet,2000; 355: 2237–2244
  Google Scholar
• 73. Moreno H., Grande-Pérez A., Domingo E., Martín V.: Arenavirusesand lethal mutagenesis. Prospects for new ribavirin-basedinterventions. Viruses, 2012; 4: 2786–2805
  Google Scholar
• 74. Morris A.B., Cu-Uvin S., Harwell J.I., Garb J., Zorrilla C., VajaranantM., Dobles A.R., Jones T.B., Carlan S., Allen D.Y.: Multicenterreview of protease inhibitors in 89 pregnancies. J. Acquir. ImmuneDefic. Syndr., 2000; 25: 306–311
  Google Scholar
• 75. Nikolenko G.N., Kotelkin A.T., Oreshkova S.F., Il’ichev A.A.: Mechanismsof HIV-1 drug resistance to nucleoside and non-nucleosidereverse transcriptase inhibitors. Mol. Biol., 2011; 45: 108–126
  Google Scholar
• 76. Olysio – Summary of Product Characteristics. https://ec.europa.eu/health/documents/community-register/2018/20180111139762/anx_139762_en.pdf (10.08.2018)
  Google Scholar
• 77. Ozaslan E., Yilmaz R., Simsek H., Tatar G.: Interferon therapyfor acute hepatitis C during pregnancy. Ann. Pharmacother.,2002; 36: 1715–1718
  Google Scholar
• 78. Park U.J., Hyun S.K., Kim H.T., Cho W.H., Han S.Y.: Successfultreatment of disseminated adenovirus infection with ribavirin andintravenous immunoglobulin in an adult renal transplant recipient:a case report. Transplant. Proc., 2015; 47: 791–793
  Google Scholar
• 79. Patil V.M., Gupta S.P., Samanta S., Masand N.: Current perspectiveof HCV NS5B inhibitors: a review. Curr. Med. Chem., 2011; 18: 5564–5597
  Google Scholar
• 80. Pegasys – Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/pegasys-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 81. Pfaender S., Heyden J., Friesland M., Ciesek S., Ejaz A., SteinmannJ., Steinmann J., Malarski A., Stoiber H., Tsiavaliaris G., BaderW., Jahreis G., Pietschmann T., Steinmann E.: Inactivation of hepatitisC virus infectivity by human breast milk. J. Infect. Dis., 2013;208: 1943–1952
  Google Scholar
• 82. Premji R., Roopnarinesingh N., Qazi N., Nylen E.S.: New-onsetdiabetes mellitus with exposure to ledipasvir and sofosbuvir.J. Investig. Med. High Impact Case Rep., 2015; 3: 2324709615623300
  Google Scholar
• 83. Prevymis – Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/prevymis–epar-product-information_en.pdf (10.05.2019)
  Google Scholar
• 84. Prezista – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/prezista-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 85. Puliyanda D.P., Silverman N.S., Lehman D., Vo A., BunnapradistS., Radha R.K., Toyoda M., Jordan S.C.: Successful use of oral ganciclovirfor the treatment of intrauterine cytomegalovirus infectionin a renal allograft recipient. Transpl. Infect. Dis., 2005; 7: 71–74
  Google Scholar
• 86. Raj R.S., Bonney, E.A., Phillippe M.: Influenza, immune system,and pregnancy. Reprod. Sci., 2014; 21: 1434–1451
  Google Scholar
• 87. Ribavirin – Summary of Product Characteristics. http://ec.europa.eu/health/documents/community-register/2016/20161114136472/anx_136472_en.pdf (10.08.2018)
  Google Scholar
• 88. Richwald G.A.: Imiquimod. Drugs Today, 1999; 35: 497–511
  Google Scholar
• 89. Ritonavir – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/ritonavir-mylan–epar-product-information_en.pdf (10.08.2018)
  Google Scholar
• 90. Roozbahani M., Hammersmith K.M.: Management of herpes simplexvirus epithelial keratitis. Curr. Opin. Ophthalmol., 2018; 29: 360–364
  Google Scholar
• 91. Sargel C.L., Aboud M., Forster A., Langman L.J., Tansmore J.,Mueller B.A., Smoyer W.E., Auletta J.J.: Intravenous ribavirin forparainfluenza and respiratory syncytial virus in an infant receivingextracorporeal membrane oxygenation and continuous renal replacementtherapy. J. Pediatr. Pharmacol. Ther., 2018; 23: 337–342
  Google Scholar
• 92. Sarmati L., Andreoni M., Antonelli G., Arcese W., Bruno R., CoppolaN., Gaeta G.B., Galli M., Girmenia C., Mikulska M., Pane F., PernoC.F., Picardi M., Puoti M., Rambaldi A., Svicher V., Taliani G., GentileG.: Recommendations for screening, monitoring, prevention, prophylaxisand therapy of hepatitis B virus reactivation in patientswith haematologic malignancies and patients who underwent haematologicstem cell transplantation-a position paper. Clin. Microbiol.Infect., 2017; 23: 935–940
  Google Scholar
• 93. Sato M., Honzumi K., Sato T., Hashimoto K., Watanabe M., MiyazakiK., Kawasaki Y., Hosoya M.: Sequential influenza B viral loadand susceptibility in children treated with oseltamivir and zanamivir.Pediatr. Infect. Dis. J., 2014; 33: e168–e172
  Google Scholar
• 94. Schwetz T.A., Fauci A.S.: The extended impact of human immunodeficiencyvirus/AIDS research. J. Infect. Dis., 2019; 219: 6–9
  Google Scholar
• 95. Sebivo – Summary of Product Characteristics. http://ec.europa.eu/health/documents/community-register/2017/20170623138045/anx_138045_en.pdf (10.08.2018)
  Google Scholar
• 96. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H.: Isolation of ahuman gene that inhibits HIV-1 infection and is suppressed by theviral Vif protein. Nature, 2002; 418: 646–650
  Google Scholar
• 97. Sinclair S.M., Jones J.K., Miller R.K., Greene M.F., Kwo P.Y., MaddreyW.C.: The ribavirin pregnancy registry: An interim analysis ofpotential teratogenicity at the mid-point of enrollment. Drug Saf.,2017; 40: 1205–1218
  Google Scholar
• 98. Song J.H., Kim S.Y., Shin J.K., Hong S.D., Rim K.S., Park H.N., LeeJ.H., Lee Y.B., Oh S.H., Hwang S.G.: A case of severe peripheral polyneuropathyoccurring after entecavir treatment in a hepatitis Bpatient. Korean J. Gastroenterol., 2016; 67: 216–219
  Google Scholar
• 99. Soota K., Maliakkal B.: Ribavirin induced hemolysis: a novel mechanismof action against chronic hepatitis C virus infection. WorldJ. Gastroenterol., 2014; 20: 16184–16190
  Google Scholar
• 100. Sovaldi – Summary of Product Characteristics. https://ec.europa.eu/health/documents/community-register/2014/20140116127595/anx_127595_en.pdf (10.08.2018)
  Google Scholar
• 101. Spera A.M., Eldin T.K., Tosone G., Orlando R.: Antiviral therapyfor hepatitis C: Has anything changed for pregnant/lactating women?World J. Hepatol., 2016; 8: 557–565
  Google Scholar
• 102. Stock I.: Integrase inhibitors – new challenges for the treatmentof HIV-1 infections. Med. Monatsschr. Pharm., 2013; 36: 448–459
  Google Scholar
• 103. Sustiva – Summary of Product Characteristics. https://ec.europa.eu/health/documents/community-register/2017/20171215139633/anx_139633_en.pdf (10.08.2018)
  Google Scholar
• 104. Synagis – Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/synagis-epar–product-information_en.pdf (10.05.2019)
  Google Scholar
• 105. Tamiflu – Summary of Product Characteristics. https://ec.europa.eu/health/documents/community-register/2017/20170420137664/anx_137664_en.pdf (10.08.2018)
  Google Scholar
• 106. Tanaka T., Nakajima K., Murashima A., Garcia-Bournissen F.,Koren G., Ito S.: Safety of neuraminidase inhibitors against novelinfluenza A (H1N1) in pregnant and breastfeeding women. CMAJ,2009; 181: 55–58
  Google Scholar
• 107. Tatum H., Thuluvath P.J., Lawitz E., Martorell C., DeMicco M.,Cohen S., Rustgi V., Ravendhran N., Ghalib R., Hanson J., ZamparoJ., Zhao J., Cooney E., Treitel M., Hughes E.: A randomized, placebo–controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J. Viral. Hepat., 2015; 22: 658–664
  Google Scholar
• 108. Telzir – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/telzir-epar-product-information_en.pdf (10.08.2018)
  Google Scholar
• 109. Tivicay – Summary of Product Characteristics. https://ec.europa.eu/health/documents/community-register/2014/20140116127569/anx_127569_en.pdf (10.08.2018)
  Google Scholar
• 110. Tivicay – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/tivicay-epar-product-information_en.pdf (10.08.2018)
  Google Scholar
• 111. Touhami S., Qu L., Angii M., Bojanova M., Touitou V., LehoangP., Rozenberg F., Bodaghi B.: Cytomegalovirus anterior uveitis: Clinicalcharacteristics and long-term outcomes in a French series. Am.J. Ophthalmol., 2018; 194: 134–142
  Google Scholar
• 112. U.S. Food and Drug Administration. https://www.fda.gov(10.05.2019)
  Google Scholar
• 113. Usach I., Melis V., Peris J.E.: Non-nucleoside reverse transcriptaseinhibitors: a review on pharmacokinetics, pharmacodynamics,safety and tolerability. J. Int. AIDS Soc., 2013; 16: 1–14
  Google Scholar
• 114. Usoro A., Batts A., Sarria J.C.: Intravenous foscarnet with topicalcidofovir for chronic refractory genital herpes in a patient with AIDS.J. Investig. Med. High Impact Case Rep., 2015; 3: 2324709615621095
  Google Scholar
• 115. Valganciclovir – Summary of Product Characteristics. http://leki.urpl.gov.pl/files/30_ValganciclovirTeva_450.pdf (10.08.2018)
  Google Scholar
• 116. van Hemert F.J., Berkhout B., Zaaijer H.L.: Differential bindingof tenofovir and adefovir to reverse transcriptase of hepatitis B virus.PLoS One, 2014; 9: e106324
  Google Scholar
• 117. Vemilidy – Summary of Product Characteristics.http://ec.europa.eu/health/documents/community-register/2018/20180528141192/anx_141192_en.pdf (10.08.2018)
  Google Scholar
• 118. Vere Hodge R.A., Field H.J.: Antiviral agents for herpes simplexvirus. Adv. Pharmacol., 2013; 67: 1–38
  Google Scholar
• 119. Viekirax – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/viekirax-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 120. Viramune – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/viramune–epar-product-information_en.pdf (10.08.2018)
  Google Scholar
• 121. Viregyt K – Summary of Product Characteristics. http://leki.urpl.gov.pl/files/Viregyt_K_kaps_100mg.pdf (10.05.2019)
  Google Scholar
• 122. Vistide – Summary of Product Characteristics. https://ec.europa.eu/health/documents/community-register/2005/200506249862/anx_9862_en.pdf (10.08.2018)
  Google Scholar
• 123. Wilhelmus K.R.: Antiviral treatment and other therapeutic interventionsfor herpes simplex virus epithelial keratitis. CochraneDatabase Syst. Rev., 2015; 1: CD002898
  Google Scholar
• 124. Wimmersberger Y., Gervaix A., Baglivo E.: VZV retinal vasculitiswithout systemic infection: diagnosis and monitoring with quantitativepolymerase chain reaction. Int. Ophthalmol. 2010; 30: 73–75
  Google Scholar
• 125. Workowski K.A., Bolan G.A.: Sexually transmitted diseasestreatment guidelines, 2015. MMWR Recomm. Rep., 2015; 64: 1–137
  Google Scholar
• 126. Wyles D.L., Ruane P.J., Sulkowski M.S., Dieterich D., LuetkemeyerA., Morgan T.R., Sherman K.E., Dretler R., Fishbein D., GatheJ.C. Jr, Henn S., Hinestrosa F., Huynh C., McDonald C., Mills A., et al.:Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV- 1 N. Engl. J. Med., 2015; 373: 714–725
  Google Scholar
• 127. Yager J.E., Magaret A.S., Kuntz S.R., Selke S., Huang M.L., CoreyL., Casper C., Wald A.: Valganciclovir for the suppression of Epstein–Barr virus replication. J. Infect. Dis., 2017; 216: 198–202
  Google Scholar
• 128. Yan Z., Qiao B., Zhang H., Wang Y., Gou W.: Effectiveness of telbivudineantiviral treatment in patients with hepatitis B virus-associatedglomerulonephritis: A 104-week pilot study. Medicine, 2018; 97: e11716
  Google Scholar
• 129. Yost R., Pasquale T.R., Sahloff E.G.: Maraviroc: a coreceptorCCR5 antagonist for management of HIV infection. Am. J. HealthSyst. Pharm., 2009; 66: 715–726
  Google Scholar
• 130. Yu Y.Y., Zhang D.Z., Miao X.H., Zhu C.L., Zhou X.Q., Yu H., SiC.W.: Foscarnet sodium for treatment in patients with severe chronichepatitis B. Zhonghua Gan Zang Bing Za Zhi, 2006; 14: 814–816
  Google Scholar
• 131. Zandi S., Bodaghi B., Garweg J.G.: Review for disease of the year:Treatment of viral anterior uveitis: a perspective. Ocul. Immunol.Inflamm., 2018; 26: 1135–1142
  Google Scholar
• 132. Zeffix – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/zeffix-epar-product-information_en.pdf (10.08.2018)
  Google Scholar
• 133. Zepativer – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/zepatier-epar–product-information_en.pdf (10.08.2018)
  Google Scholar
• 134. Zerit – Summary of Product Characteristics. https://www.ema.europa.eu/documents/product-information/zerit-epar-product–information_en.pdf (10.08.2018)
  Google Scholar
• 135. Zhang K., Cao H., Liang J., Shu X., Sun H., Li G., Xu Q.: CONSORT:Effects of adding adefovirdipivoxil to peginterferon alfa-2aat different time points on HBeAg-positivepatients: A prospective,randomized study. Medicine, 2016; 95: e4471
  Google Scholar
• 136. Zhong L., Wang W., Ma M., Gou L., Tang X., Song H.: Chronic activeEpstein-Barr virus infection as the initial symptom in a Janus kinase 3 deficiencychild: Case report and literature review. Medicine, 2017; 96: e7989
  Google Scholar

Pełna treść artykułu